New antibiotic approved for acute bacterial skin infectionsFDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.
FDA’s updated fluoroquinolone warnings: What urologists should know. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections
Selecting topical regimens for cataract patients
Selecting topical regimens for cataract patientsEyecare practitioners who deal with patients in the perioperative period are well aware of the need for topical therapy. In most cases, a combination of a steroid, a nonsteroidal anti-inflammatory drug (NSAID), and an antibiotic will be used for a few days before the day of surgery and then for a period afterward.
Using dry eye treatments for sick corneasDid you ever consider that those tools in your dry eye arsenal are also good for acutely sick eyes? I recently had a patient who drove this point home…even to my ophthalmology partner.
FDA warns about Cipro, other antibacterialsFDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.
New antibacterial treatment for plague approvedFDA has approved moxifloxacin (Avelox) for the treatment of patients with plague. Avelox has been approved under the Animal Efficacy Rule, because it was not ethical to conduct human trials.
Moxifloxacin, ciprofloxacin connected to uveitis riskA recent study published in JAMA Ophthalmology found that current use of moxifloxacin (Avelox, Bayer) or ciprofloxacin (Cipro, Bayer) appears to increase the risk for uveitis.
Most fluoroquinolones use not connected with glaucoma riskA recent study published in the Journal of Glaucoma found that there was no detected increase in glaucoma risk with current, recent, or past use of systemic fluoroquinolones, but did find a minimal statistically significant increased risk with distant use.
FDA warns of neuropathy risks with fluoroquinolonesAccording to FDA, the risk of peripheral neuropathy occurs only with fluoroquinolones that are taken by mouth or by injection.